Cardina : Yeah. AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader on Saturday when it announced plans to … Alexion — whose board is chaired by former AstraZeneca CEO David Brennan — has a pipeline of 11 molecules across more than 20 clinical development programs in rare diseases and beyond that will underpin AstraZeneca's, which is the second-largest research and development pipeline in the industry after Roche Holding AG. Download PDF. At AstraZeneca, we’re looking for Precision Medicine Experts, to join our Precision Medicine and Biosamples department in Sweden or the UK. Advanced medicines that demonstrate both strong clinical performance and benefits to patients (Select pipeline highlights as of August 2020) * Partnered assets. AstraZeneca had been getting into the immunology space and that pipeline of drugs is heavily in immunology. AstraZeneca’s Respiratory & Immunology medical resource centre for healthcare professionals. Pipeline. We’re focused on providing medicines that make a real difference to patient care, and precision medicine is at the heart of our commitment to patient centric science and innovation. msn back to msn home ... had failed to gain traction and opposed its plan to buy rivals to diversify its research pipeline. Welcome to AZ MedX. Accept. Download PDF. Download PDF. Key 2021 Events. Pharmaceutical Pipeline . AstraZeneca Central America and Caribbean ... our R+D pipeline and our product launches. Key 2020 Events . We have 40 years of experience in the respiratory field and a very strong portfolio of products marketed. Respiratory & Immunology. Discover the latest advances and approaches in asthma, COPD and more. The cash and equity takeover will bolster AstraZeneca’s primary focus on immunology, bringing a pipeline of experimental drugs targeting rare diseases as it rushes to develop a vaccine against the coronavirus. This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies. AstraZeneca, the developer of one of the pharmaceutical industry’s first COVID-19 vaccine, recently announced that it will acquire US-based Alexion for $39 billion.. Find out more. January 26, 2021. AstraZeneca’s respiratory pipeline of investigational therapies across the various stages of clinical development. January 26, 2021. AstraZeneca to buy Alexion for $39 billion to expand in immunology. They're looking for the deal to close in the third quarter of 2021. Late Stage Pipeline. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The cash-and-stock takeover will deepen AstraZeneca’s core focus on immunology, by bringing a pipeline of experimental drugs that target rare diseases as it races to develop a coronavirus vaccine. January 26, 2021.